10:47 AM EDT, 10/21/2024 (MT Newswires) -- Arcutis Canada, a subsidiary of Arcutis Biotherapeutics ( ARQT ) , said Monday it has received approval from Health Canada for Zoryve to treat seborrheic dermatitis in patients aged 9 and older.

Trial data showed notable improvement in signs and symptoms, with the majority of patients experiencing reduced itching, scaling and redness, common burdens associated with seborrheic dermatitis, the company said.

Shares of the company were about 2% lower in recent trading.

Price: 8.56, Change: -0.16, Percent Change: -1.83